MySubsidy

Scheme for Strengthening of Medical Device Industry (SMDI) - Marginal Investment Scheme for Reducing Import Dependence (MISRID)

Department of Pharmaceuticals · Central government

SMDI's capital subsidy funds domestic manufacturing of key medical device components and raw materials to cut import dependency.

Closed. Applications closed on 24 July 2026. The details below describe the most recent cycle.

Key facts

Subsidy amount
Up to ₹10,00,00,000
Instrument
Subsidy
Deadline
24 July 2026
Disbursement
Reimbursed after spend

About this scheme

The Scheme for Strengthening of Medical Device Industry (SMDI) is run by the Department of Pharmaceuticals under the Ministry of Chemicals & Fertilizers, Government of India. Its purpose is to reduce India's dependence on foreign suppliers in the medical device sector. The Marginal Investment Scheme for Reducing Import Dependence (MISRID) sits within SMDI and targets the localisation of components, raw materials and accessories needed to make medical devices, in-vitro diagnostics (IVDs) included.

Indian medical device manufacturers have long imported critical inputs, which exposes them to supply chain disruption and raises production costs. MISRID offers financial incentives to domestic companies that invest in manufacturing such inputs locally, with the aim of lowering that import reliance.

The scheme's goal is to build an indigenous ecosystem for medical device manufacturing and strengthen India's ability to make quality devices at affordable prices. It covers local production of items such as sensors, embedded systems, optical filters, electrodes and medical-grade materials. Through this, SMDI-MISRID seeks to encourage innovation, generate employment and position India as a global hub for medical device manufacturing.

This push forms part of the 'Make in India' vision. It also supports public health by keeping essential medical devices available within the country, particularly when global health crises disrupt supply.

Who can apply

Eligible business forms
Private limited company, Limited liability partnership, One person company, Partnership firm, Sole proprietorship
Udyam registration
Not specified
MSME registration
Not specified
DPIIT startup recognition
Not specified
GST registration
Not specified
Where the business may be based
Not restricted

- Central or State Government organisations, companies or LLPs, and Special Purpose Vehicles (SPVs) registered in India under the Companies Act or the Societies Registration Act are eligible. - Medical device or in-vitro diagnostic manufacturers qualify, whether they already operate facilities or plan to produce key components, input materials, or accessories. - Manufacturers of critical raw materials — for instance polymer, glass, metal, textile, or paper intended for medical grade use — are eligible. - Importers who plan to move into manufacturing any medical device or IVD appearing on the GTE list may apply.

How to apply

1. Open the official SMDI portal at https://smdi.lsssdc.in/. 2. Go to the application section for the Marginal Investment Scheme for Reducing Import Dependence (MISRID). 3. Complete the online application form with all required details and register your organisation. 4. Upload the supporting documents sought, which usually comprise company registration certificates, financial statements, detailed project proposals, investment plans, and technical specifications of the components/materials to be manufactured. 5. File your application no later than the deadline of July 24, 2026. 6. Track your application status on the portal and reply to any queries raised by the scheme administrators. 7. Applicants who are shortlisted move on to the evaluation stages, which involve technical review and committee appraisals.

Apply on the issuer's sitesupport-smdi@lsssdc.in

How applications are assessed

Applications for the SMDI-MISRID scheme pass through several stages of scrutiny before approval. A Project Management Agency (PMA) first appraises each submission, checking that it is complete and satisfies the basic eligibility criteria.

Proposals that clear this stage go before a Technical Committee, which examines their technical feasibility, innovation content and strategic importance to manufacturing. The Scheme Steering Committee then grants final approval, confirming that the projects taken up support the scheme's aims of building up the medical device industry and lowering reliance on imports.

Frequently asked questions

What is the primary objective of the MISRID scheme?

The scheme aims to cut India's reliance on imports by encouraging the manufacture of critical components, raw materials and accessories for medical devices, in-vitro diagnostic devices included.

Who is eligible to apply for this scheme?

Central and State Government organisations, Companies or LLPs registered in India, and Special Purpose Vehicles (SPVs) registered under the Companies Act or the Societies Registration Act may apply. This includes manufacturers of medical devices, IVDs and critical raw materials, as well as importers planning to move into manufacturing.

What is the maximum subsidy amount I can receive?

Capital subsidy under the scheme is capped at ₹10 Crore and is paid as reimbursement. The applicable rate — 20%, 15% or 10% — is determined by the company's annual turnover, with smaller companies qualifying for the higher percentage of their investment.

What kind of activities are eligible for this subsidy?

Manufacturing key components, raw materials and accessories for medical devices and IVDs counts as an eligible activity; this takes in sensors, embedded systems, optical filters, electrodes, antigens/antibodies, polymer tubing, metal tubing and medical-grade packaging materials.

Is co-financing required for this scheme?

Yes — because the incentive is a reimbursement-based capital subsidy, the applicant must fund the initial investment themselves and will receive a percentage of it back, meaning co-financing on their part is required.

What is the project completion timeline?

Approved projects must be completed within two years of final approval, though a one-year extension may be permitted in specific circumstances.

Sectors

  • Health Pharma Biotech
  • Medical Devices
  • Healthcare Manufacturing
  • Import Substitution
  • Capital Subsidy
  • Invitro Diagnostics
  • Pharmaceuticals

Details last verified on 18 September 2026. Source: the issuer's published information.